Trump touts pharma deals for cheaper Medicaid drugs; details sparse

The Trump administration announced agreements with pharmaceutical companies to lower drug prices for state Medicaid programs, claiming all states will participate. However, key details—such as which drugs are covered, the magnitude of discounts, and the legal basis—remain undisclosed, leaving the program's scope and impact uncertain. This marks a notable policy push on drug pricing, but its market and fiscal effects depend on the missing specifics.